Justification and Approval for Other than Full and Open Competition SANOFI 09112026 _Redacted.pdf

This is a Sole Source Justification under Federal Supply Schedule submitted by the U.S. Department of State's Global Acquisitions office on behalf of the Office of Global Operations.

The Department of State seeks approval to issue a firm-fixed-price delivery order on a sole-source basis through the Department of Veterans Affairs Sanofi Pasteur Federal Supply Schedule contract (36F79722D0104) for proprietary High Dose Fluzone and Flublok Influenza vaccines for the 2026-2027 flu season. The estimated order value is $68,964.00. The vaccines are required to immunize embassy immunocompromised family members and provide disease prevention against three influenza strains. Cold chain storage must be maintained throughout delivery, with the Office of Logistics Management coordinating timely distribution to embassies and consulates prior to the start of the 2026-2027 flu season. The justification for sole-source procurement is that Sanofi Pasteur is the only manufacturer of high dose Fluzone and Flublok egg-free influenza vaccines, and these specific pediatric vaccines represent the first Trivalent (later corrected to Quadrivalent) Flu vaccines approved by the FDA. The Contracting Officer has determined the anticipated contract action represents best value and will evaluate the resultant price for reasonableness prior to award. No market research alternatives were identified, as Sanofi Pasteur maintains a monopoly on these specialized vaccine formulations.